The LRRK2 flaw causes around five percent of inherited cases of Parkinson's, according to an extrapolation of these figures.
The drug, however, is no longer available to Kaufman or other Parkinson's patients in clinical trials.
According to the company, the agency said that safety issues would preclude the drug's being given to new patients but that it would consider allowing Amgen to resume treating the existing patients.
The activists have the right to one protest on Thursday afternoons.
Parkinson's disease occurs when a group of brain cells which produce a chemical called dopamine begin to malfunction and eventually die.
